Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
FR0012333284
Thu, 15.06.2023
ABIVAX
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
The award recognizes a significant capital market transaction in the biotech sector
Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023
P [ … ]
Thu, 15.06.2023
ABIVAX
Abivax receives “Capital Market Transaction of the Year Award” at the European Mediscience Awards 2023
The award recognizes a significant capital market transaction in the biotech sector
Abivax received the award for its oversubscribed EUR 130M cross-over financing at market price with top-tier US and European Biotech investors in February 2023
P [ … ]
Thu, 08.06.2023
ABIVAX
Abivax stock included in MSCI Indexes
As of June 1st, the Abivax stock is represented in the MSCI Indexes
The MSCI Indexes reflect the evolution of the world’s equity markets to support investors building effective portfolios based on risk and return assessments
PARIS, France, June 8, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 [ … ]
Thu, 08.06.2023
ABIVAX
Abivax stock included in MSCI Indexes
As of June 1st, the Abivax stock is represented in the MSCI Indexes
The MSCI Indexes reflect the evolution of the world’s equity markets to support investors building effective portfolios based on risk and return assessments
PARIS, France, June 8, 2023 – 6:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 [ … ]
Thu, 08.06.2023
ABIVAX
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
Shareholders approved all proposed resolutions
PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune syst [ … ]
Thu, 08.06.2023
ABIVAX
Abivax releases the results of its June 5, 2023 ordinary and extraordinary general meeting
Shareholders approved all proposed resolutions
PARIS, France, June 6, 2023 – 6:00 p.m. (CEST) – Abivax SA (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune syst [ … ]
Thu, 08.06.2023
ABIVAX
Abivax appoints Ida Hatoum as Chief People Officer
As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions
Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry
PARIS, Fran [ … ]
Thu, 08.06.2023
ABIVAX
Abivax appoints Ida Hatoum as Chief People Officer
As Chief People Officer of Abivax, Ida Hatoum will be leading the organizational strategy to build and strengthen the Abivax team in the United States and Europe across all functions
Ida has a proven track record in talent acquisition and development in the biopharmaceutical industry
PARIS, Fran [ … ]
Mon, 15.05.2023
ABIVAX
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
PARIS, France, May 15, 2023 – 7:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat [ … ]
Mon, 15.05.2023
ABIVAX
Abivax announces its ordinary and extraordinary general meeting of June 5, 2023, and the availability of the preparatory documents
PARIS, France, May 15, 2023 – 7:00 p.m. (CEST) – Abivax (Euronext Paris: FR0012333284 – ABVX), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat [ … ]